High immune presence (>80th percentile in the cohort) was observed across a range of tumor types including tumors with SMARCB1/A4 loss (chordoma, rhabdoid tumors), neuroblastoma, rhabdomyosarcoma and osteosarcoma, and high grade CNS tumors (Fig. 5C, D). This evidence concerns the gene SMARCB1 and central nervous system neoplasm.